Print ISSN:-2581-5555
Online ISSN:-2456-9542
CODEN : IIJCDU
Original Article
Author Details :
Volume : 4, Issue : 1, Year : 2019
Article Page : 11-16
https://doi.org/10.18231/j.ijcaap.2019.003
Abstract
The humongous cost and long-time duration of new drug development surpasses the rewards in form benefit to patients and cost recovered by the pharmaceutical firms. The problem which this situation gives rise to are productivity gap, pressure by sky soaring prices, incompetency with respect to beneficial generics and issues from regulatory authorities. One advanced approach of drug development which shows potential to tackle these issues is what we refer to as drug repositioning. Drug repurposing is an economical option, time duration to bring a new drug to the market is lesser. There are different approaches to drug repositioning including two broad categories – data driven (computational approaches) and experimental approach. Data driven approaches include - signature matching, molecular docking, genetic mapping, pathway mapping, retrospective clinical analysis, novel data sources while the experimental approach include assays defining target drug interactions, phenotypic screening. Drug repositioning is associated with challenges like chances of failure, regulatory barriers, patency issues and lack of financial incentives. For maximizing the drug repositioning process and to increase its productivity challenges posed to drug repositioning need to be addressed.
Keywords: Drug repositioning, Computational approach, Experimental approach.
How to cite : Singh D, Jain S, Adhaulia G, Barua S, Sachan A K, Drug repositioning: Achievements, advancements and barriers. IP Int J Compr Adv Pharmacol 2019;4(1):11-16
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.